With the utilization of three categories of anti-cancer drugs, namely BRAF-targeted, MEK-targeted, and Immune checkpoint inhibitors (ICIs) on melanoma, significantly improved OS had been achieved in advanced-stage patients6–8. This evidence concerns the gene MAP2K7 and melanoma.